Navigation

Friday, May 10th 2019

08.15 – 09.30

Atrial Fibrillation

Chairpersons: Carlos Morillo (Calgary, CA), Geneviève Derumeaux (Créteil, FR), Ali Oto (Ankara, TR), Andrea Menafoglio (Bellinzona, CH)

08.15 – 08.30
Antiarrhythmic drugs for Atrial Fibrillation – State of the art

Gheorghe Dan (Bucharest, RO)

08.30 – 08.45
Advances in curative approaches

Angelo Auricchio (Lugano, CH)

08.45 – 09.00
Neurocognitive function in atrial fibrillation and anticoagulation: lessons from the Swiss atrial fibrillation cohort study

Stefan Osswald (Basel, CH)

09.00 – 09.15
Stroke prevention: state of the art

Antoni Martinez-Rubio (Barcelona, ES)

09.15 – 09.30
Discussion

09.30 – 10.10

Chronic Heart Failure: A Paradigm Shift

Chairpersons: Georg Noll (Zurich, CH), Giuseppe Rosano (London, GB), Hector Ventura (New Orleans, US)

09.30 – 09.45
A paradigm shift in the treatment of heart failure

Karl Swedberg (Gothenburg, SE)

09.45 – 10.00
Devices for management of heart failure

Frank Ruschitzka (Zurich, CH)

10.00 – 10.10
Discussion

10.10 – 10.40

Coffee Break

10.40 – 11.15

Key Lecture – Acute Heart Failure

Chairpersons: Basil Lewis (Haifa, IL), Thomas Suter (Bern, CH), Maurizio Volterrani (Rome, IT), Marcello Di Valentino (Bellinzona, CH)

10.40 – 11.00
Acute heart failure: death risk higher than heart attack but care lags 30 years behind

Christian Mueller (Basel, CH)

11.00 – 11.15
Discussion

11.15 – 11.45

State of the Art Lecture

Chairpersons: Thomas Kahan (Stockholm, SE), Ferenc Follath (Lugano, CH), Juan Carlos Kaski (London, GB), Stefan Agewall (Oslo, NO)

11.15 – 11.45
Translational medicine and reverse in cardiovascular pharmacotherapy

Thomas Luescher (London, GB / Zurich, CH)

11.45 – 12.45

New Antidiabetic Drugs Improve Cardiovascular Morbidity and Mortality in Patients with Coronary Artery Disease and Diabetes
A Boehringer Ingelheim (Schweiz) GmbH Symposium

Chairpersons: Alexandre Fredenrich (Bellinzona, CH / Nice, FR ), Heinz Drexel (Feldkirch, AT), Michael Zellweger (Basel, CH), Francesco Paneni (Rome, IT / Zurich, CH)

11.45 – 12.00
SGLT2 inhibitors: a change of paradigm in the treatment of cardiac failure in patients with Type 2 diabetes

Philippe van de Borne (Brussels, BE)

12.00 – 12.15
Beyond CVOT trials: SGLT2 inhibitors in Heart failure patients without diabetes

Francesco Paneni (Rome, IT / Zurich, CH)

12.15 – 12.30
Emerging REAL-world Data versus clinical randomized trials and Type 2 diabetes guidelines

Heinz Drexel (Feldkirch, AT)

12.30 – 12.45
Discussion

12.45 – 13.15

KEY LECTURE

Chairpersons: Heinz Drexel (Feldkirch, AT), Philippe van de Borne (Brussels, BE), Marco Pons (Lugano, CH)

12.45 – 13.05
Cardiovascular effects of incretin-based therapies: lessons from the trials testing GLP1 RAs

Aldo Maggioni (Firenze, IT)

13.05 – 13.15
Discussion

13.15 – 14.00

The Emerging Role of PCSK9 Inhibitors after ACS
A SANOFI SYMPOSIUM

Chairpersons: Alberico L. Catapano (Milan, IT), Alberto Lorenzatti (Cordoba, AR), Giorgio Noseda (Mendrisio, CH), Heinz Drexel (Feldkirch, AT)

13.15 – 13.30
Tackling the residual risk

Alvaro S. Liprandi (Buenos Aires, AR)

13.30 – 13.45
The emerging role of PCSK9 inhibitors after an acute coronary event: successful return after an Odyssee

François Mach (Geneva, CH)

13.45 – 14.00
Discussion

13.15 – 14.15

Lunch

14.15 – 15.15

Arterial Hypertension

Chairpersons: Georg Noll (Zurich, CH), Celso Amodeo (São Paulo, BR), Franco Muggli (Lugano, CH)

14.15 – 14.30
The hypertension paradox – more uncontrolled disease despite improved therapy

Gianfranco Parati (Milan, IT)

14.30 – 14.45
Target blood pressure in patients at high cardiovascular risk

Thomas Kahan (Stockholm, SE)

14.45 – 15.00
Antihypertensive treatment in the very elderly

Georg Noll (Zurich, CH)

15.00 – 15.15
Discussion

15.15 – 15.40

ASPIRIN IN PRIMARY PREVENTION: A PARADIGM CHANGE?

15.15 – 15.30
Lessons from the ASPREE trial

John McNeil (Melbourne, AU)

15.30 – 15.40
Discussion

15.40 – 16.20

Ventricular and Atrial Remodeling – The Road to Heart Failure and Stroke: Future Approaches.
A joint Session with the French Society of Cardiology

Chairpersons: Antoni Martinez-Rubio (Barcelona, ES), Gheorghe Dan (Bucharest, RO), Denis Cokkinos (Athens, GR)

15.40 – 15.55
Cardiac remodeling in metabolic cardiomyopathy

Geneviève Derumeaux (Créteil, FR)

15.55 – 16.10
Left ventricular architecture, long-term reverse remodeling and clinical outcome: lessons from the REVERSE trial

Jean-Claude Daubert (Rennes, FR)

16.10 – 16.20
Discussion

16.20 – 16.45

ISCP Awards

Augusto Gallino (Bellinzona, CH), Juan Carlos Kaski (London, GB)

16.20 – 16.30
Brief Historical Closing remarks

Wilhelm Rutishauser (Geneva, CH)

16.30 – 16.40
ISCP Posters Awards

16.40 – 16.45
Announcement of the 2020 ISCP annual meeting Miami

Hector Ventura (New Orleans, US)

16.20

End of the meeting